Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RaySearch Laboratories ABCHIX:RAYBS 93 EV-to-EBIT is 21.19 as of Aug. 08, 2026, which is 33% below its 10-year median of 31.74. GuruFocus rates CHIX:RAYBS with a GF Score™ of 93/100 and a GF Value™ of kr178.26 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 471 Healthcare Providers & Services companies, RaySearch Laboratories AB ranks worse than 63.91% on this metric.
The historical rank and industry rank for RaySearch Laboratories AB's EV-to-EBIT or its related term are showing as below:
CHIX:RAYBs'
s EV-to-EBIT Range Over the Past 10 Years
Min: -4052.82 Med: 31.74 Max: 445.05
Current: 21.19
During the past 13 years, the highest EV-to-EBIT of RaySearch Laboratories AB was 445.05. The lowest was -4052.82. And the median was 31.74.
CHIX:RAYBs's EV-to-EBIT is ranked worse than 63.91% of 471
companies
in the Healthcare Providers & Services industry
Industry Median: 16.04
vs CHIX:RAYBs: 21.19
RaySearch Laboratories AB (CHIX:RAYBs) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
RaySearch Laboratories AB's Enterprise Value for the quarter that ended in Mar. 2026 was kr6,123 Mil.
RaySearch Laboratories AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr285 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RaySearch Laboratories AB EV-to-EBIT Related Terms
RaySearch Laboratories AB EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:RAYBS vs VEEV, BTSG, HQY: EV-to-EBIT Comparison
For the Health Information Services subindustry, RaySearch Laboratories AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RaySearch Laboratories AB EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, RaySearch Laboratories AB's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where RaySearch Laboratories AB's EV-to-EBIT falls into.
RaySearch Laboratories AB's current Enterprise Value is kr6,037 Mil.
RaySearch Laboratories AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr285 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RaySearch Laboratories AB (CHIX:RAYBS) has a EV-to-EBIT of 21.19 as of Aug. 08, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on RaySearch Laboratories AB and its competitors. This is 33% below median its historical median of 31.74. According to the industry distribution chart, RaySearch Laboratories AB ranks #301 out of 471 companies in the Healthcare Providers & Services industry, placing it in the top 63.9%.
Is RaySearch Laboratories AB's EV-to-EBIT too high?
RaySearch Laboratories AB's current EV-to-EBIT of 21.19 is 33% below median its 10-year median of 31.74. The Healthcare Providers & Services industry median EV-to-EBIT is 16.04. RaySearch Laboratories AB's value of 21.19 is 32.1% above this industry median. Based on the distribution chart, RaySearch Laboratories AB ranks #301 out of 471 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, RaySearch Laboratories AB has a GF Score™ of 93/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RaySearch Laboratories AB's EV-to-EBIT compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, RaySearch Laboratories AB ranks #301 out of 471 companies for EV-to-EBIT. This places RaySearch Laboratories AB in the lower half of its industry. The industry median EV-to-EBIT is 16.04. RaySearch Laboratories AB's value of 21.19 is 32.1% above this benchmark. While the company's 10-year median is 31.74 vs. the industry median of 16.04, RaySearch Laboratories AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 16.04, based on 471 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RaySearch Laboratories AB's current EV-to-EBIT of 21.19 is 32.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on RaySearch Laboratories AB and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 16.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RaySearch Laboratories AB's current EV-to-EBIT is 21.19, which is 33% below median its own 10-year median of 31.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaySearch Laboratories AB stock overvalued right now?
Based on GuruFocus' analysis, RaySearch Laboratories AB (CHIX:RAYBS) is currently considered Significantly Overvalued. The stock's GF Value™ is kr178.26, compared to a current price of kr234.70 — trading 31.7% above its estimated fair value. The current EV-to-EBIT is 21.19, which is 33% below median its 10-year median of 31.74 and 32.1% above the Healthcare Providers & Services industry median of 16.04. RaySearch Laboratories AB's overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For RaySearch Laboratories AB (CHIX:RAYBS), the current EV-to-EBIT is 21.19 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RaySearch Laboratories AB (CHIX:RAYBS) Overvalued in 2026?
Based on GuruFocus' analysis, RaySearch Laboratories AB stock appears to be overvalued.
The current stock price of kr234.70 is trading 31.7% above its estimated GF Value™ of kr178.26.
GuruFocus considers RaySearch Laboratories AB to be Significantly Overvalued.
Key valuation signals for CHIX:RAYBS:
EV-to-EBIT: 21.19 (33% below median its 10-year median of 31.74)
GF Value™: kr178.26 vs. price of kr234.70 (31.7% above fair value)
Industry Position: 32.1% above the Healthcare Providers & Services median (#301 of 471)
No single metric tells the full story. See the CHIX:RAYBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RaySearch Laboratories AB is a Sweden-based medical technology company. The company develops software solutions for improved cancer treatment. The company develops and markets the RayStation treatment planning system and RayCare oncology information system to clinics all over the world and distributes products through licensing agreements with medical technology companies. Its geographic segments consist of the Americas, Asia-Pacific & Middle East, Europe, and the rest of world.
93GF Score
Get the complete analysis for CHIX:RAYBS
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:RAYBS has been successfully added to your 
